论文部分内容阅读
目的:探讨重组人乳铁蛋白(rhLF)对体外培养的3株人卵巢癌细胞的影响。方法:体外培养SKOV3、HO-8910、HO-8910PM,用MTT法评价rhLF对三者的生长抑制作用。结果:重组人乳铁蛋白对3株细胞均有抑制作用并呈剂量依赖关系,对SKOV3的抑制较另两株显著,不同浓度的rhLF对SKOV3增殖的抑制率达40.95%、62.03%、72.63%,实验对照组细胞无明显的抑制效果。结论:重组人乳铁蛋白可以有效抑制卵巢癌细胞的体外增殖,为其作为新的肿瘤生物治疗剂奠定了理论基础。
Objective: To investigate the effect of recombinant human lactoferrin (rhLF) on three human ovarian cancer cells cultured in vitro. Methods: SKOV3, HO-8910 and HO-8910PM were cultured in vitro. The effects of rhLF on the growth inhibition were evaluated by MTT assay. RESULTS: Recombinant human lactoferrin had inhibitory effect on three cell lines in a dose-dependent manner. The inhibitory effect on SKOV3 was significantly different from that of the other two strains. The inhibitory rates of different concentrations of rhLF on SKOV3 proliferation were 40.95%, 62.03%, 72.63% , Experimental control group cells no significant inhibitory effect. CONCLUSION: Recombinant human lactoferrin can effectively inhibit the proliferation of ovarian cancer cells in vitro and lay a theoretical foundation for its application as a new tumor bio-therapeutic agent.